Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / NRx Pharmaceuticals FDA ANDA Review
Regulatory regulatory milestone

NRx Pharmaceuticals FDA ANDA Review

Analysis based on 6 articles · First reported Aug 07, 2026 · Last updated Aug 07, 2026

Sentiment
40
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The FDA's completion of first-cycle review is a positive regulatory milestone for NRx Pharmaceuticals, potentially accelerating the path to market for its ketamine product. This could boost investor confidence and the company's stock price, though final approval is not guaranteed.

Biopharmaceuticals
Event Summary

NRx Pharmaceuticals, Inc. announced that the U.S. United States — Food and Drug Administration (FDA) has completed its first-cycle review of the company's Abbreviated New Drug Application (ANDA) for preservative-free ketamine. The company will host a conference call on August 10, 2026, to discuss the regulatory path to approval and commercial plans. The call will feature CEO Jonathan Javitt, Chief Commercial Officer Glenn Tyson, and Director Chaim Hurvitz, former president of Teva International Group. NRx is developing NRX-100 (preservative-free intravenous ketamine) for suicidal depression and other CNS disorders, and has also filed a New Drug Application with a request for a National Priority Voucher.

Key Actions
80 NRx Pharmaceuticals announced
40 NRx Pharmaceuticals scheduled conference call
Entities Involved
stock
NRx Pharmaceuticals
NRx Pharmaceuticals is the central entity; the FDA's review completion is a key milestone for its lead product candidate, potentially improving its commercial prospects and stock valuation.
Importance 100.0 Sentiment 60.0
govactor
United States — Food and Drug Administration
The FDA is the regulatory authority that completed the first-cycle review of NRx's ANDA, a critical step in the approval process for the company's ketamine product.
Importance 80.0 Sentiment 0.0
per
Jonathan Javitt
Jonathan Javitt, CEO and founder, will lead the conference call and is a key spokesperson for the company's regulatory and commercial strategy.
Importance 40.0 Sentiment 0.0
per
Glenn Tyson
Glenn Tyson, Chief Commercial Officer, will participate in the call to discuss commercial plans, reflecting his role in the company's go-to-market strategy.
Importance 20.0 Sentiment 0.0
per
Chaim Hurvitz
Chaim Hurvitz, a director with experience at Teva, will join the call, lending industry expertise to the discussion of regulatory and commercial matters.
Importance 20.0 Sentiment 0.0
stock
Sun Pharma
Teva is mentioned as the former employer of Chaim Hurvitz, providing context to his background but not directly involved in this event.
Importance 10.0 Sentiment 0.0
exch
Nasdaq
Nasdaq is the exchange where NRx Pharmaceuticals is listed; the event may influence the company's stock performance on this exchange.
Importance 10.0 Sentiment 0.0
Relationships
United States — Food and Drug Administration related ↔ Sun Pharma
United States — Food and Drug Administration related ↔ Nasdaq
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.